1. Blumenfeld J.D., Sealey J.E., Alderman M.H., Cohen H., Lappin R., Catanzaro D.F., Laragh J.H.. Plasma renin activity in the emergency department and its independent association with acute myocardial infarction.
Am J Hypertens 13:2000;855–863.
2. Alderman M.H., Madhavan S., Ooi W.L., Cohen H., Sealey J.E., Laragh J.H.. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension.
N Engl J Med 324:1991;1098–1104.
3. Alderman M.H., Ooi W.L., Cohen H., Madhavan S., Sealey J.E., Laragh J.H.. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients.
Am J Hypertens 10:1997;1–8.
4. Gonzalez M.C., Cohen H.W., Sealey J.E., Laragh J.H., Alderman M.H.. Enduring direct association of baseline plasma renin activity with all-cause and cardiovascular mortality in hypertensive patients.
Am J Hypertens 24:2011;1181–1186.
5. Brunner H.R., Laragh J.H., Baer L., Newton M.A., Goodwin F.T., Krakoff L.R., Bard R.H., Bühler F.R.. Essential hypertension: renin and aldosterone, heart attack and stroke.
N Engl J Med 286:1972;441–449.
6. Verma S., Gupta M., Holmes D.T., Xu L., Teoh H., Gupta S., Yusuf S., Lonn E.M.. Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study.
Eur Heart J 32:2011;2135–2142.
7. Latini R., Masson S., Anand I., Salio M., Hester A., Judd D., Barlera S., Maggioni A.P., Tognoni G., Cohn J.N.; Val-HeFT Investigators. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT.
Eur Heart J 25:2004;292–299.
8. Vergaro G., Emdin M., Iervasi A., Zyw L., Gabutti A., Poletti R., Mammini C., Giannoni A., Fontana M., Passino C.. Prognostic value of plasma renin activity in heart failure.
Am J Cardiol 108:2011;246–251.
9. Rouleau J.L., Packer M., Moyé L., de Champlain J., Bichet D., Klein M., Rouleau J.R., Sussex B., Arnold J.M., Sestier F., Parker J.O., McEwan P., Bernstein V., Cuddy T.E., Lamas G., Gottlieb S.S., McCans J., Nadeau C., Delage F., Wun C.C.C., Pfeffer M.A.. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril.
J Am Coll Cardiol 24:1994;583–591.
10. Muhlestein J.B., May H.T., Bair T.L., Prescott M.F., Horne B.D., White R., Anderson J.L.. Relation of elevated plasma renin activity at baseline to cardiac events in patients with angiographically proven coronary artery disease.
Am J Cardiol 106:2010;764–769.
11. Masson S., Solomon S., Angelici L., Latini R., Anand I.S., Prescott M., Maggioni A.P., Tognoni G., Cohn J.N.; Val-Heft Investigators. Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT).
J Card Fail 16:2010;964–970.
12. Campbell D.J., Nussberger J., Stowasser M., Danser A.H., Morganti A., Frandsen E., Ménard J.. Activity assays and immunoassays for plasma renin and prorenin: information provided and precautions necessary for accurate measurement.
Clin Chem 55:2009;867–877.
13. Parikh N.I., Gona P., Larson M.G., Wang T.J., Newton-Cheh C., Levy D., Benjamin E.J., Kannel W.B., Vasan R.S.. Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study.
Eur Heart J 28:2007;2644–2652.
14. Alderman M.H., Cohen H.W., Sealey J.E., Laragh J.H.. Pressor responses to antihypertensive drug types.
Am J Hypertens 23:2010;1031–1037.
15. Sim J.J., Bhandari S.K., Shi J., Kalantar-Zadeh K., Rasgon S.A., Sealey J.E., Laragh J.H.. Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system.
Am J Hypertens 25:2012;379–388.
16. Egan B.M., Basile J.N., Rehman S.U., Davis P.B., Grob C.H. 3rd, Riehle J.F., Walters C.A., Lackland D.T., Merali C., Sealey J.E., Laragh J.H.. Plasma renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial.
Am J Hypertens 22:2009;792–801.
17. Meade T.W., Cooper J.A., Peart W.S.. Plasma renin activity and ischemic heart disease.
N Engl J Med 329:1993;616–619.
18. Sever P.S., Chang C.L., Prescott M.F., Gupta A., Poulter N.R., Whitehouse A., Scanlon M.. Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Eur Heart J 33:2012;2970–2979.
19. Dahlöf B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O'Brien E., Ostergren J.. ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
Lancet 366:2005;895–906.
20. Bhandari S.K., Pashayan S., Liu I.L., Rasgon S.A., Kujubu D.A., Tom T.Y., Sim J.J.. 25-hydroxyvitamin D levels and hypertension rates.
J Clin Hypertens (Greenwich) 13:2011;170–177.
21. Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F. 3rd, Feldman H.I., Kusek J.W., Eggers P., Van Lente F., Greene T., Coresh J.; CKD EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate.
Ann Intern Med 150:2009;604–612.
22. Sealey J.E.. Plasma renin activity and plasma prorenin assays.
Clin Chem 37:1991;1811–1819.
23. Sim J.J., Handler J., Jacobsen S.J., Kanter M.H.. Systemic implementation strategies to improve hypertension: the Kaiser Permanente Southern California experience.
Can J Cardiol 30:2014;544–552.
24. Laragh J.. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension.
Am J Hypertens 14:2001;837–854.
25. Macfelda K., Weiss T.W., Kaun C., Breuss J.M., Zorn G., Oberndorfer U., Voegele-Kadletz M., Huber-Beckmann R., Ullrich R., Binder B.R., Losert U.M., Maurer G., Pacher R., Huber K., Wojta J.. Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes.
J Mol Cell Cardiol 34:2002;1681–1691.
26. Campbell D.J.. Critical review of prorenin and (pro)renin receptor research.
Hypertension 51:2008;1259–1264.
27. Sim J.J., Shi J., Al-Moomen R., Behayaa H., Kalantar-Zadeh K., Jacobsen S.J.. Plasma renin activity and its association with ischemic heart disease, congestive heart failure, and cerebrovascular disease in a large hypertensive cohort.
J Clin Hypertens (Greenwich) 16:2014;805–813.
28. Sim J.J., Shi J., Calara F., Rasgon S., Jacobsen S., Kalantar-Zadeh K.. Association of plasma renin activity and aldosterone-renin ratio with prevalence of chronic kidney disease: the Kaiser Permanente Southern California cohort.
J Hypertens 29:2011;2226–2235.
29. Atlas S.A., Case D.B., Yu Z.Y., Laragh J.H.. Hormonal and metabolic effects of angiotensin converting enzyme inhibitors. Possible differences between enalapril and captopril.
Am J Med 77:1984;13–17.
30. Azizi M., Ménard J., Bissery A., Guyenne T.T., Bura-Rivière A., Vaidyanathan S., Camisasca R.P.. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
J Am Soc Nephrol 15:2004;3126–3133.
31. McMurray J.J., Pitt B., Latini R., Maggioni A.P., Solomon S.D., Keefe D.L., Ford J., Verma A., Lewsey J.; Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.
Circ Heart Fail 1:2008;17–24.
32. Solomon S.D., Appelbaum E., Manning W.J., Verma A., Berglund T., Lukashevich V., Cherif Papst C., Smith B.A., Dahlöf B.; Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.
Circulation 119:2009;530–537.
33. Pfeffer M.A., McMurray J.J., Velazquez E.J., Rouleau J.L., Køber L., Maggioni A.P., Solomon S.D., Swedberg K., Van de Werf F., White H., Leimberger J.D., Henis M., Edwards S., Zelenkofske S., Sellers M.A., Califf R.M.; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
N Engl J Med 349:2003;1893–1906.
34. Dahlöf B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., Wedel H.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet 359:2002;995–1003.
35. Cohn J.N., Tognoni G.; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
N Engl J Med 345:2001;1667–1675.
36. Turner S.T., Schwartz G.L., Chapman A.B., Beitelshees A.L., Gums J.G., Cooper-DeHoff R.M., Boerwinkle E., Johnson J.A., Bailey K.R.. Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension.
Am J Hypertens 23:2010;1014–1022.
37. Mulatero P., Rabbia F., Milan A., Paglieri C., Morello F., Chiandussi L., Veglio F.. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.
Hypertension 40:2002;897–902.
38. Katz F.H., Romfh P., Smith J.A.. Diurnal variation of plasma aldosterone, cortisol and renin activity in supine man.
J Clin Endocrinol Metab 40:1975;125–134.
39. Naito Y., Tsujino T., Matsumoto M., Okuda S., Sakoda T., Ohyanagi M., Masuyama T.. The mechanism of distinct diurnal variations of renin-angiotensin system in aorta and heart of spontaneously hypertensive rats.
Clin Exp Hypertens 31:2009;625–638.
40. Sim J.J., Yan E.H., Liu I.L., Rasgon S.A., Kalantar-Zadeh K., Calhoun D.A., Derose S.F.. Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population.
J Hypertens 29:2011;1553–1559.